Active Filter(s):
Details:
Results from the “FAITH” combination trial shows that addition of Umifenovir did not demonstrate any additional benefit over Favipiravir alone in moderate COVID-19 patients. Umifenovir did not show superior clinical outcomes when added to Favipiravir treatment.
Lead Product(s): Favipiravir,Umifenovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2020
Details:
Early treatment with combination therapy will be evaluated for safety and efficacy as it is emerging as an effective approach in shortening duration of virus shedding, decreasing cytokine response, and facilitating early discharge of patients.
Lead Product(s): Favipiravir,Umifenovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2020